Cronos Group announces acquisition of CanAdelaar B.V. for $67 Million; shares rise

According to Investing, Cronos Group Inc. (NASDAQ:CRON) (TSX:CRON) announced this week that it has entered into an agreement to acquire CanAdelaar B.V., described as the largest cannabis company operating in the Netherlands' adult use cannabis pilot program. Detailed information is available at Investing.

Traded at $2.47, Cronos has a market capitalization of approximately $951 million. Its shares have risen 26% in the last six months.

The acquisition will cost $67 million in upfront cash, with additional contingent payments based on CanAdelaar's performance in 2026 and 2027. According to the company's statement, the initial consideration represents about 1.4 times CanAdelaar's last twelve months' revenue and 2.4 times its EBITDA.

CanAdelaar operates a 540,000 square foot facility in Voorne aan Zee, Netherlands, and is the only industrial-scale greenhouse grower among the ten licensed producers in the country's Wietexperiment program. The company produces approximately 20,000kg of dried flowers annually and sells to nearly all 72 participating coffee shops in the pilot program.

The Wietexperiment was officially launched in April 2025, establishing a regulated supply chain in ten participating municipalities, with a scheduled duration of four years, extendable for up to 18 months.

CanAdelaar reported revenue of $47.3 million and EBITDA of $28.2 million for the twelve months ended September 30, 2025. Cronos' Chairman of the Board, President, and CEO, Mike Gorenstein, stated: "Our acquisition of CanAdelaar is a financially attractive and highly strategic transaction that will establish a strategic presence in Europe".

InvestingPro data shows that Cronos holds more cash than debts on its balance sheet, with a current liquidity ratio of 22.45. The company achieved a 19% revenue growth in the last twelve months and has a financial health score rated as "EXCELLENT", trading slightly below its Fair Value. The transaction was approved by Cronos' Board of Directors and is expected to be completed in early 2026, subject to regulatory approvals.

In recent news, Cronos Group released its third-quarter 2025 results, with an earnings per share (EPS) of $0.07, surpassing the forecast of $0.02 (250% surprise). However, revenue fell short of expectations, recording $36.34 million against the anticipated $37.3 million.